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OBJECTIVE—The sodium-calcium exchanger isoform 1
(NCX1) regulates cytoplasmic calcium (Ca
2
c) required for insu-
lin secretion in -cells. NCX1 is alternatively spliced, resulting in
the expression of splice variants in different tissues such as
NCX1.3 and -1.7 in -cells. As pharmacological inhibitors of
NCX1 splice variants are in development, the pharmacological
proﬁle of -cell NCX1.3 and -1.7 and the cellular effects of NCX1
inhibition were investigated.
RESEARCH DESIGN AND METHODS—The patch-clamp
technique was used to examine the pharmacological proﬁle of
the NCX1 inhibitor KB-R7943 on recombinant NCX1.3 and -1.7
activity. Ca
2 imaging and membrane capacitance were used to
assess the effects of KB-R7943 on Ca
2
c and insulin secretion in
mouse and human -cells and islets.
RESULTS—NCX1.3 and -1.7 calcium extrusion (forward-mode)
activity was 16-fold more sensitive to KB-R7943 inhibition
compared with cardiac NCX1.1 (IC50s  2.9 and 2.4 vs. 43.0
mol/l, respectively). In single mouse/human -cells, 1 mol/l
KB-R7943 increased insulin granule exocytosis but was without
effect on -cell glucagon granule exocytosis. KB-R7943 also
augmented sulfonylurea and glucose-stimulated Ca
2
c levels and
insulin secretion in mouse and human islets, although KB-R7943
was without effect under nonstimulated conditions.
CONCLUSIONS—Islet NCX1 splice variants display a markedly
greater sensitivity to pharmacological inhibition than the cardiac
NCX1.1 splice variant. NCX1 inhibition resulted in glucose-
dependent increases in Ca
2
c and insulin secretion in mouse and
human islets. Thus, we identify -cell NCX1 splice variants as
targets for the development of novel glucose-sensitive insulino-
tropic drugs for type 2 diabetes. Diabetes 59:1686–1693, 2010
I
t is now widely accepted that decreased -cell
function, resulting in inadequate insulin secretion, is
a key component of type 2 diabetes pathophysiology
(1,2). Indeed, pharmacological agents such as sulfo-
nylureas are used clinically to stimulate insulin secretion
in type 2 diabetes. However, there is no absolute require-
ment for elevated glucose in order for sulfonylureas to
stimulate insulin secretion via inhibition of -cell ATP-
sensitive K
 channels (KATP channels). Consequently,
hypoglycemia is a signiﬁcant concern with sulfonylurea
therapy (3,4), and there is much interest in the develop-
ment of insulinotropic drugs with improved glucose
sensitivity.
In the pancreatic -cell, cytoplasmic calcium (Ca
2
c)
levels rise as a direct consequence of glucose metabolism,
via closure of KATP channels, triggering Ca
2 entry and
subsequent Ca
2-mediated exocytosis of insulin granules
(5). Therefore, partial inhibition of any protein involved in
the removal of Ca
2
c during -cell excitation should
augment insulin secretion only when -cells are stimu-
lated. One potential candidate protein is the sodium-
calcium exchanger isoform 1 (NCX1), which is a
membrane protein involved in the extrusion of Ca
2
c in
many tissues, including the pancreatic -cell (6–8). NCX1
is a bidirectional ion exchanger that predominately ex-
trudes Ca
2
c during forward-mode (FM) operation when
Ca
2
c is elevated. NCX1 may also operate in Ca
2 inﬂux
mode (reverse mode; RM) that contributes to the patho-
physiological increases in Ca
2
c and Ca
2
c overload that
occurs during cardiac ischemia/reperfusion injury (9–11).
In this regard, pharmacological inhibitors have been de-
veloped as putative cardioprotective agents to reduce RM
NCX1 activity and ameliorate the deleterious Ca
2
c over-
load in cardiac tissue (12–14). While such NCX inhibitors
favor pathophysiological cardiac RM NCX1 inhibition
(13,15–18), their effects on the physiological Ca
2
c extru-
sion via FM NCX1 activity in -cells have not been
determined. Theoretically, partial pharmacological inhibi-
tion of FM NCX1 activity in -cells should delay Ca
2
c
clearance, leading to an increased Ca
2
c exocytotic signal
and enhanced insulin secretion that is sensitive to glucose.
NCX1 is encoded by the SLC8A1 gene (6,19), which is
alternatively spliced, leading to the expression of different
splice variants in various tissues (20) with pancreatic
-cells expressing the NCX1.3 and -1.7 splice variants
(8,21) compared with NCX1.1 in the heart. Importantly, we
have recently shown that -cell NCX1 splice variants
display markedly different biophysical properties and acyl
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variant (21). However, the pharmacological proﬁle of
-cell NCX1.3 and -1.7 splice variants and the cellular
effects of their inhibition have not been elucidated.
Therefore, the aims of this study were to determine 1)
the sensitivities of the -cell NCX1.3 and -1.7 splice
variants to the NCX inhibitor KB-R7943 and 2) the effects
of partial NCX1 inhibition on -cell exocytosis, mouse and
human islet Ca
2
c, and insulin secretion under basal or
glucose-/KCl sulfonylurea-stimulated conditions.
RESEARCH DESIGN AND METHODS
Molecular biology. The rat NCX1.4 cDNA (22) and the Ad-shNCX1/Ad-
scramble adenoviruses (23) were generously provided by Dr. J. Lytton
(University of Calgary) and Dr. G.N. Pierce (University of Manitoba), respec-
tively. Cloning and generation of the human NCX1 splice variants were
described previously (21).
Cell culture and transfection. tsA201 cells were maintained in DMEM
supplemented with 25 mmol/l glucose, 2 mmol/l L-glutamine, 10% FCS, and
0.1% penicillin and streptomycin in a humidiﬁed incubator at 37°C with 5%
CO2. tsA201 cells were cotransfected with an NCX1 cDNA clone and a green
ﬂuorescent protein plasmid using the calcium phosphate technique (24).
Experiments were performed 24–72 h after transfection.
Islet isolation and dissociation. Islets from BALB/c mice were isolated by
collagenase (Sigma-Aldrich, Oakville, ON, CA) digestion of the pancreas,
puriﬁed by Ficoll density gradient and then handpicked. Human islets from
three donors were provided by Dr. James Shapiro (University of Alberta) and
the Administrative and Bioinformatics Coordinating Center Human Islet
Distribution Program at the University of Alberta. Islets were dispersed into
single cells 2 h postisolation by gentle agitation in a Ca
2-free buffer
containing 0.0025% trypsin and plated on poly-D-lysine glass coverslips. Mouse
and human islet cells were cultured in medium 199 supplemented with 5.6
mmol/l glucose, 0.2% NaHCO3, 10% FCS, and 0.1% penicillin/streptomycin and
in DMEM supplemented with 5.6 mmol/l glucose, 10% FCS, and 0.1% penicillin/
streptomycin, respectively.
Electrophysiology. The excised inside-out patch-clamp technique was used
to measure recombinant FM NCX1 activity (22  1°C) from transfected tsA201
cells as previously described (25). Unidirectional FM currents were elicited by
rapidly changing the Ca
2
c from 1 mol/l to 3.2 mmol/l. The membrane
patch was held at 0 mV, and NCX1 currents were measured and analyzed using
the Axopatch 200B ampliﬁer and Clampex 9.2 software (Axon Instruments,
Foster City, CA). Peak current was deﬁned as the maximal current recorded
postactivation, and late current was taken as the current amplitude measured
1 min postactivation. Inactive exchangers were pre-exposed to KB-R7943 for
1.5 min prior to a 1-min activation in its presence. Total NCX1 current was
measured as the area under the curve (AUC) during the entire activation
period. Concentration-response curves were ﬁtted with the Hill equation.
Calcium imaging. Islets from BALB/c mice were cultured in medium 199 for
24–48 h at 37°C, 5% CO2. Islets were loaded for 60 min at room temperature
with the Ca
2-sensitive ﬂuorescent probe Fura-2AM (16 mol/l, in a 1:1 vol/vol
DMSO: pluronic acid mixture; Invitrogen, Burlington, ON, CA) in bath solution
containing (in mmol/l) 140 NaCl, 5 KCl, 2 CaCl2, 1.4 MgCl2, 10 HEPES, and 2.8
glucose, pH 7.4. The KCl concentration was changed to 15 mmol/l when
increased K

o was used as a depolarizing stimulus. The concentration of NaCl
was adjusted accordingly to maintain osmolarity. Islets were washed and
placed in an open chamber on the microscope stage and superfused with
various bath solutions at 1 ml/min at 35  1°C. A photomultiplier detection
system (PTI, London, ON, CA) with FeliX32 software was used for data
acquisition and analysis. Ratio-metric analysis was used to estimate changes
in Ca
2
c. Islets were excited at 340/380 nm (1 Hz), and the emitted 510-nm
light was quantiﬁed. The average change in Ca
2
c for tolbutamide experiments
was taken as the AUC for 12 min (6-min drug application and 6-min washout).
For the glucose experiments, the average change in Ca
2
c was taken as the
AUC for 20 min following peak onset. Changes in basal Ca
2
c were measured
as the average 340/380 nm value over the last minute. The rate at which the
average Ca
2
c decreased once the stimulus was removed was taken as the
time required for the ﬂuorescent signal to drop to 10% of the peak value.
In situ NCX1 knockdown and pharmacology. For in situ NCX1 knock-
down, BALB/c islet cells were infected with an adenovirus (100 multiplicity of
infection [MOI]) to deliver NCX1 short-hairpin RNA (shRNA) (Ad-shNCX1) or
an adenoviral vector expressing a scrambled shRNA sequence as the control
(Ad-scramble) and cultured in medium 199 for 72 h postinfection. For the in
situ pharmacology experiments, cells were exposed to 1 mol/l KB-R7943 for
a minimum of 5 min.
Membrane capacitance. To determine depolarization-induced exocytosis
from single - and -cells, membrane capacitance changes were measured as
described previously (21). Brieﬂy, exocytosis was elicited with a train of 10
500-ms depolarizations (at 1 Hz) from 70 to 0 mV. The total exocytosis was
taken as the sum of the capacitance increases during the depolarizing pulses.
Capacitance changes were normalized to the initial cell size (as fF/pF). For
calcium infusion experiments, the pipette calcium concentration was buffered
to 200 nmol/l with EGTA, and capacitance was measured as previously
described (26). Primary -/-cells were positively identiﬁed post hoc by
immunostaining for insulin or glucagon, respectively.
Immunoblotting. MIN6 cells were infected with 100 MOI of either Ad-
shNCX1 or Ad-scramble and cultured for 72 h. A total of 40 g of protein lysate
were subjected to SDS-PAGE, transferred to polyvinylidene diﬂouride mem-
branes (Millipore, Etobicoke, ON, CA), probed with the NCX-1 R3F1 mono-
clonal antibody (Swant, Bellinzona, CH), detected with peroxidase-conjugated
secondary antibody (GE Healthcare, Mississauga, ON, CA), visualized by
chemiluminescence (ECL-Plus; GE Healthcare), and exposed to X-ray ﬁlm
(Kodak, Rochester, NY). Protein-loading controls were -actin (Santa Cruz
Biotechnology, Santa Cruz, CA) and total acetyl-CoA carboxylase (ACC) (Cell
Signaling, Technology, Boston, MA). Quantiﬁcation of NCX-1 protein expres-
sion was performed using densitometry and ImageJ software.
Glucose-stimulated insulin secretion assays. Islets were preincubated for
2 h (with a fresh solution change after 1 h) at 37°C, in low-glucose
Krebs-Ringer bicarbonate solution  1 mol/l KB-R7943 (in mmol/l: 140 NaCl,
5 KCl, 2 CaCl2, 1.4 MgCl2, 10 HEPES, 24 NaHCO3, 0.5% BSA, and 2.8 glucose,
pH 7.4). Groups of 25 islets were perifused for 10 min at 37°C with low-glucose
KRB solution followed by 40 min with high-glucose (11.1 mmol/l) KRB at a
rate of 0.25 ml/min using a Suprafusion 1000 System (Brandel, Gaithersburg,
MD). Fractions were collected every 2 min, and changes in insulin secretion
are expressed either as ng/ml per 25 islets or as a fold change (11.1/2.8
mmol/l). Insulin was quantiﬁed via enzyme-linked immunosorbent assay
according to the manufacturer’s instructions (ALPCO Diagnostics, Salem,
NH).
Experimental compounds. KB-R7943 (Tocris Bioscience, Ellisville, MO)
was dissolved in DMSO as a 100 mmol/l stock. Tolbutamide (Sigma-Aldrich,
Oakville, ON, CA) was dissolved in DMSO as a 20 mmol/l stock. Stock
solutions were serially diluted in DMSO prior to use such that the ﬁnal
concentration of DMSO was 0.1% in all solutions when using KB-R7943 or
tolbutamide.
Statistical analysis. Statistical signiﬁcance was assessed using the paired or
unpaired Student t test or a one-way ANOVA with a Bonnferoni post hoc test,
where required. P 	 0.05 was considered signiﬁcantly different, and data are
expressed as means  SE.
RESULTS
FM activity of -cell NCX1 splice variants can be
inhibited by KB-R7943. Past studies exploring the phar-
macological inhibition of NCX1 have primarily focused on
the cardiac splice variant (NCX1.1) and its RM of opera-
tion, as this mode contributes to calcium loading observed
in ischemia/reperfusion injury. The general consensus is
that NCX1 inhibitors preferentially inhibit the inactivating
Ca
2 inﬂux mode (RM) compared with the Ca
2 efﬂux
mode (FM) (13,15–18) that displays no inactivation.
We have recently reported that, in contrast to the cardiac
NCX1.1 splice variant, -cell NCX1 splice variants
(NCX1.3 and -1.7) exhibit signiﬁcant inactivation during
FM operation (Fig. 1A) (21). Therefore, we tested the
notion that NCX inhibitors, such as KB-R7943, may inhibit
the FM activity of the -cell NCX1.3 and -1.7 splice variants
that display FM inactivation. As previously reported, 5
mol/l KB-R7943 failed to inhibit total FM NCX1.1 activity
(Fig. 1B and G) (27) but caused a signiﬁcant reduction in
total FM NCX1.3 (69.45  3.12%, n  10) (Fig. 1C and G)
and NCX1.7 (65.57  3.20%, n  10) (Fig. 1D and G)
activity. In addition, KB-R7943 displayed a concentration-
dependent inhibition of FM activity (Fig. 1E), exhibiting a
greater potency for inhibition of the -cell splice variants,
NCX1.3 (IC50  2.90  0.27 mol/l), and NCX1.7 (IC50 
2.40  0.15 mol/l) compared with the cardiac NCX1.1
splice variant (IC50  42.97  2.36 mol/l).
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tivity to KB-R7943. We have previously reported that the
presence of exon B within the alternative splicing region
of NCX1 proteins bestows FM inactivation (21). Since
NCX1 splice variants differ only in the exon composition in
the alternative splicing region, this region likely confers
FM sensitivity to KB-R7943. Examination of the exon
composition between NCX1.1 (ACDEF) and NCX1.3 (BD)
and NCX1.7 (BDF) points to the role of exon B in
bestowing the increased KB-R7943 sensitivity (Fig. 1F). To
examine this directly, exon A in NCX1.1 was substituted
for exon B, generating NCX1.11 (BCDEF) (Fig. 1F).
NCX1.11 displays FM KB-R7943 sensitivity similar to that
observed for NCX1.3 and NCX1.7 (64.3  2.92% reduction
in total current, n  8) (Fig. 1G). Similarly, replacing exon
B with A in rat NCX1.3 (NCX1.4) (Fig. 1F) dramatically
decreased FM KB-R7943 sensitivity (Fig. 1G). Therefore,
the presence of exon B in NCX1 splice variants bestows
the increased KB-R7943 sensitivity to FM inhibition.
KB-R7943 is a more potent blocker of the late com-
ponent of FM -cell NCX1 splice variants. Previous
reports show that KB-R7943 preferentially blocks the late
(or steady-state) component of RM NCX1 current, presum-
ably by either stabilizing the I1 inactivated state or by
increasing the rate of inactivation (27,28). To examine
whether KB-R7943 exhibits a similar effect on FM currents
that inactivate, concentration-response curves for NCX1.3
and -1.7 were generated. KB-R7943 exhibits a signiﬁcantly
greater potency for FM late current (IC50  2.15  0.26
mol/l, NCX1.3; 1.72  0.09 mol/l, NCX1.7) compared
with peak current (IC50  5.59  0.28 mol/l, NCX1.3;
4.71  0.15 mol/l, NCX1.7) for both NCX1.3 (Fig. 2A and
B) and NCX1.7 (Fig. 2C and D), and these effects readily
wash out (Fig. 2A and C).
KB-R7943 inhibits -cell L-type calcium channels.
KB-R7943 is not selective for NCX1 and is known to inhibit
the cardiac L-type calcium channel at higher concentra-
tions (IC50s 3–7 mol/l) (29,30). Consequently, the effect of
KB-R7943 was tested on endogenous L-type calcium chan-
nels in -cells using the whole-cell patch-clamp technique.
Application of 1 mol/l KB-R7943 to mouse and human
-cells caused a 32.66  3.74% (n  7) and 29.54  3.18%
reduction in total Ba
2 current, respectively. Therefore,
the possibility exists that this nonspeciﬁc effect of KB-
R7943 on the -cell L-type calcium channel may paradox-
ically reduce calcium entry and subsequent insulin
secretion. Accordingly, the precise cellular consequences
of NCX1 inhibition on calcium signaling and exocytosis
were determined in the following experiments.
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FIG. 1. KB-R7943 inhibits FM NCX1 activity in a splice variant–
dependent manner. A: Representative current recordings of NCX1.1,
-1.3, and -1.7 splice variants demonstrating that the -cell NCX1 splice
variants, NCX1.3 and -1.7, display FM inactivation, whereas the cardiac
NCX1.1 splice variant does not. B–D: Representative current record-
ings illustrating that FM NCX1.1 activity is resistant to inhibition by 5
mol/l KB-R7943, whereas NCX1.3 and -1.7 displayed marked KB-
R7943 inhibition. E: KB-R7943 concentration-inhibition curves for
NCX1.1, -1.3, and -1.7 FM currents. F: Diagrammatic representation of
the alternative splicing region exon composition for various NCX1
splice variants. G: Grouped KB-R7943 (5 mol/l) inhibition data for FM
NCX1.1, -1.11, -1.3, -1.4, and -1.7 currents. *P < 0.05, n  7–10 patches
per group. 0  <1 mol/l Ca
2. NCX1 proteins were expressed in
tsA201 cells.
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FIG. 2. The late FM NCX1.3 and -1.7 currents are more sensitive to
KB-R7943 inhibition (3 mol/l) compared with peak currents. Repre-
sentative recordings of NCX1.3 (A) and -1.7 (C) FM currents before
(control) and after the application of 3 mol/l KB-R7943. Concentra-
tion-response curves for NCX1.3 (B) and -1.7 (D) late and peak
KB-R7943 FM current inhibition demonstrating that KB-R7943 prefer-
entially inhibits the late FM currents compared with peak FM currents.
*P < 0.05, n  4–10 patches per concentration. 0  <1 mol/l Ca
2.
NCX1 proteins were expressed in tsA201 cells.
-CELL SODIUM-CALCIUM EXCHANGE
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islet cytoplasmic calcium levels. To determine whether
partial inhibition of -cell NCX1 is effective at increasing
islet Ca
2
c levels, changes in Ca
2
c were monitored by
Fura-2 ratiometric ﬂuorometry. Upon the application of 20
mol/l tolbutamide, mouse islets constantly superfused
with 2.8 mmol/l glucose exhibited a signiﬁcant increase in
Ca
2
c (a 0.45  0.04 increase in the 340/380 nm ratio, n 
9) (Fig. 3A and B), conﬁrming in this system that sulfonyl-
urea drugs stimulate -cells even at low glucose concen-
trations. Upon a second tolbutamide challenge, the
elevation in Ca
2
c decreased by 21.87  4.58% (n  11)
(Fig. 3A). In contrast, application of 1 mol/l KB-R7943 (a
concentration that yields a partial 25% inhibition of
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FIG. 3. Calcium imaging of mouse islets. A: Application of 20 mol/l tolbutamide (Tolb) to islets superfused with 2.8 mmol/l glucose increases
Ca
2
c levels that are lower upon a second tolbutamide application. B: In contrast, the addition of 1 mol/l KB-R7943 signiﬁcantly increases the
magnitude of Ca
2
c elevation observed during the second application of tolbutamide. KB-R7943 does not increase Ca
2
c levels when applied alone
in the presence of 2.8 mmol/l glucose. Ci: Grouped data showing that KB-R7943 signiﬁcantly increases Ca
2
c levels (*P < 0.05, n  6–11 islets)
in the presence of tolbutamide or KCl. Cii: Grouped data showing that in the absence of the tolbutamide or KCl stimulatory signal, KB-R7943 does
not increase Ca
2
c (n  6–9 islets). D: Grouped data indicating that the rate at which Ca
2
c returned to basal levels is slower in the presence of
KB-R7943 for both tolbutamide and KCl (*P < 0.05, n  6–9 islets). E: Increasing glucose from 2.8 to 11.1 mmol/l elicited increases in Ca
2
c,
whereas 1 mol/l KB-R7943 did not increase Ca
2
c at 2.8 mmol/l glucose but signiﬁcantly increased Ca
2
c in 11.1 mmol/l glucose when compared
with 11.1 mmol/l glucose alone. Grouped data showing that 1 mol/l KB-R7943 signiﬁcantly increased the peak (peak) (Fi) and average Ca
2
c
(AUC) in response to 11.1 mmol/l glucose (Fii). *P < 0.05, n  9 islets per group.
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the presence of 2.8 mmol/l glucose failed to signiﬁcantly
increase Ca
2
c levels (Fig. 3B) but signiﬁcantly augmented
Ca
2
c when added concurrently with tolbutamide (19.95 
6.92% increase in Ca
2
c n  9) (Fig. 3B and C). Similar
results were obtained when the extracellular concentra-
tion of KCl was raised to 15 mmol/l (Fig. 3C). One mol/l
KB-R7943 also signiﬁcantly slowed the rate of calcium
clearance after removal of the tolbutamide/KCl challenge
(Fig. 3D). Application of 1 mol/l KB-R7943 alone at low
(2.8 mmol/l) glucose did not alter Ca
2
c (Fig. 3E) yet
caused a signiﬁcant 83.44  18.27% increase to the peak
Ca
2
c response (Fig. 3E and F) as well as increased
average Ca
2
c by 79.98  8.73% (n  9) (Fig. 3F) during an
11.1 mmol/l glucose challenge.
NCX1 inhibition increases calcium-dependent exocy-
tosis in -cells but not -cells. To examine the cellular
consequences of decreased FM NCX1 activity, we mea-
sured whole-cell capacitance changes elicited by a train of
depolarizing pulses in mouse and human -cells with a
reduction in NCX1 activity (Fig. 4). Adenoviral delivery of
shRNA for NCX1 (Ad-shNCX1) increased the capacitance
response of the mouse -cells (Fig. 4A) when compared
with adenoviral delivery of the scrambled shNCX1 se-
quence (Ad-scramble). This resulted in an overall increase
in the total capacitance change from 29.22  6.44 (n  8)
to 62.22  8.25 (n  12) fF/pF (Fig. 4A). Independent
Western blot analysis on MIN6 cell lysates demonstrates
that infection of MIN6 cells with Ad-shNCX1 results in a
25% reduction of NCX1 protein expression (25.76 
3.36% and 24.09  3.46% [n  3] vs. noninfected control
with -actin and total ACC used as loading controls,
respectively) (Fig. 4B). Similarly, partial inhibition of FM
NCX1 activity with 1 mol/l KB-R7943 increased the
capacitance response (Fig. 4C) and increased the change
in total capacitance from 36.04  4.87 (n  10) to 118.22 
33.48 (n  6) fF/pF (Fig. 4C).
To determine whether KB-R7943 elicits any indirect
effects on the exocytotic process independently of NCX1
inhibition, exocytosis was stimulated by direct infusion of
200 nmol/l free Ca
2 in the presence or absence of
KB-R7943, and the corresponding increase in capacitance
was measured. In either condition, the rate at which the
capacitance increased was not signiﬁcantly different in the
presence or absence of KB-R7943 (Fig. 4D). These results
suggest that KB-R7943 does not enhance exocytosis
when Ca
2
c is inﬁnitely buffered, thus minimizing the
contribution of calcium extrusion via NCX1.
The effect observed with mouse -cells was also seen
with human -cells, where 1 mol/l KB-R7943 increased
the capacitance response (Fig. 4E) and increased the total
change in capacitance from 13.01  5.64 (n  6) to
100.20  28.82 ((n  4) fF/pF (Fig. 4E). In direct contrast,
application of 1 mol/l KB-R7943 did not signiﬁcantly alter
the depolarization-induced capacitance response observed
in mouse -cells (Fig. 4F).
NCX1 inhibition augments insulin secretion in a glu-
cose-dependent manner. The calcium and exocytosis
data indicate that partial NCX1 inhibition should stimulate
islet insulin secretion in a glucose-sensitive manner. To
test this notion directly, mouse and human islet perifusion
experiments were performed in the presence or absence
of 1 mol/l KB-R7943 and insulin secretion measured in
response to increasing glucose from 2.8 to 11.1 mmol/l. In
both mouse and human islets, KB-R7943 signiﬁcantly
enhanced ﬁrst- and second-phase insulin secretion stimu-
lated by 11.1 mmol/l glucose (Fig. 5A and B) but was
without effect at 2.8 mmol/l glucose.
DISCUSSION
Our data represents the ﬁrst pharmacological character-
ization of -cell/islet NCX1.3 and -1.7 FM currents. Inter-
estingly, we observed that the FM activity of these -cell/
islet NCX1 splice variants can be potently inhibited by
KB-R7943 and that this block is dependent upon the
presence of FM inactivation (Fig 1C and D). To investigate
this directly, we examined the KB-R7943 sensitivity of
various NCX1 splice variants. NCX1 splice variants that
contain exon A (NCX1.1 [ACDEF] and NCX1.4 [AD]) do
not exhibit FM inactivation (21) and thus exhibit a resis-
tance to block by KB-R7943 (Fig 1F and G). In contrast,
NCX1 splice variants that contain exon B (NCX1.3 [BD],
NCX1.7 [BDF], and NCX1.11 [BCDEF]) exhibit FM inacti-
vation (21) and are signiﬁcantly more sensitive to block by
KB-R7943 (Fig. 1F and G). This observed exon A/B depen-
dence of KB-R7943 inhibition suggests that tissue-speciﬁc
pharmacological separation may be achieved as NCX1
splice variants are selectively expressed depending on
tissue type. For example, the cardiac splice variant,
NCX1.1, does not exhibit FM inactivation, and, thus, its
physiologically relevant mode of activity is 16-fold less
sensitive to KB-R7943 inhibition compared with the -cell
NCX1.3 and -1.7 splice variants. It should be noted that
NCX1.3 and -1.7 are not exclusively expressed in the
endocrine pancreas but are also expressed in vasculature
and other tissues (20). Inhibition of FM NCX1 activity in
vascular smooth muscle may cause Ca
2-dependent vaso-
constriction and increased blood pressure, although KB-
R7943 has been recently shown to reduce vasoconstriction
via inhibition of reverse-mode NCX1 activity and reduced
Ca
2 entry (31). Therefore, the extrapancreatic effects of
selective NCX1.3 inhibition and -1.7 will require further
examination.
It has previously been shown that KB-R7943 preferen-
tially blocks the late (or steady-state) component of RM
NCX1.1 current by either increasing the rate of inactiva-
tion or by stabilizing the I1 inactivated state (27,28). Our
results demonstrate that the same may be true for the
inactivating FM currents from NCX1.3 and -1.7 (Fig. 2).
Although the exact mechanism of FM inactivation has not
been determined, the two different types of inactivation
may involve similar regions of the NCX1 protein that may
explain these observed effects of KB-R7943.
The pancreatic -cell expresses a number of intracellu-
lar and plasma membrane–bound proteins that regulate
Ca
2
c, including the plasma membrane calcium ATPase,
the plasma membrane NCX, the endoplasmic reticulum
calcium ATPase, and the mitochondrial uniporter. While
the precise contributions of NCX1 have not been fully
elucidated, it is clear that NCX1 plays an important role in
maintaining Ca
2
c homeostasis (32–35). Our results now
conﬁrm that the major role for NCX1 is the facilitation of
Ca
2
c efﬂux during periods of increased -cell excitability,
namely that partial inhibition of -cell NCX1 with KB-
R7943 further increases Ca
2
c only when Ca
2
c is already
elevated by either tolbutamide, glucose, or KCl (Fig. 3),
leading to increased exocytosis (Fig. 4) and enhanced
insulin secretion only in the presence of such a stimulus
(Fig. 5). While these results have been attributed to
KB-R7943 inhibiting FM NCX1 activity and directly veriﬁed
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handling proteins cannot be ruled out.
One additional key ﬁnding from this study is the lack of
effect of KB-R7943 on pancreatic -cell exocytosis (Fig. 4).
This suggests that glucagon secretion would be unaffected
by pharmacological inhibition of NCX1 splice variants
within the endocrine pancreas and indicate that either 1)
NCX1 does not play a major role in regulating Ca
2
c
homeostasis and hence glucagon release from -cells or 2)
-cells express an NCX1 splice variant insensitive to
pharmacological inhibition. Thus, these ﬁndings identify a
novel glucose-sensitive mechanism for insulin, but not
glucagon, secretion and provide a rationale for the devel-
opment of selective -cell NCX1 splice variant inhibitors
as a new class of glucose-sensitive insulinotropic drugs.
KB-R7943 is not exclusively selective for NCX1, and at
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FIG. 4. NCX1 inhibition and Ca
2-dependent exocytosis in - and -cells. Representative capacitance measurements and grouped data of
cumulative changes at individual pulse numbers from mouse and human -cells with reduced NCX1 expression (Ad-shNCX1), scrambled control
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B: Western blot analysis (i, ii) showing that NCX1 protein expression is only partially reduced as a result of Ad-shNCX1 infection in MIN6 cells
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(36–38). For example, KB-R7943 has been shown to inhibit
both the cardiac (IC50s 3–7 mol/l [29,30]) and -cell L-type
calcium channels at higher concentrations (this study).
Furthermore, complete NCX1 inhibition may lead to dele-
terious effects on -cell function though excess Ca
2
c
accumulation. Therefore, we selected a concentration of
KB-R7943 (1 mol/l) that obtained the desired partial
inhibition of -cell NCX1 FM activity (Fig. 1E) with the
least nonspeciﬁc inhibition of L-type calcium channel
currents. It is likely that the insulinotropic efﬁcacy of
KB-R7943 would be even greater if this molecule lacked
L-type calcium channel inhibition. It is important to note
that the marked effects on insulin secretion were observed
at 1 mol/l KB-R7943, a concentration that only inhibits
recombinant -cell NCX1.3/1.7 FM currents by 25% (Fig.
1E), suggesting that NCX1 plays an important role in Ca
2
c
clearance and that partial inhibition is sufﬁcient to en-
hance Ca
2
c and elicit stimulatory effects on insulin
secretion.
Currently available NCX1 inhibitors, such as KB-R7943,
also affect a number of ion transport processes at higher
concentrations and therefore should be considered as
“pharmacological tools” rather than as viable therapeutic
agents. Indeed, results from our preliminary in vivo intra-
peritoneal glucose tolerance tests in mice only showed a
trend toward KB-R7943 lowering blood glucose (data not
shown). Thus, the identiﬁcation of drugs with a greater
selectivity for NCX1 inhibition over other ion transport
pathways in the -cell is a necessary ﬁrst step in the
advancement of -cell NCX1 splice variants as novel
therapeutic targets. In this latter regard, newer NCX
inhibitors with a reported greater selectivity for NCX1
over other ion transport processes are in development for
cardiovascular disease, and these inhibitors may also
warrant further investigation for their splice variant selec-
tivity and insulinotropic efﬁcacy (13,15–18).
Summary. Findings from this study demonstrate for the
ﬁrst time that -cell/islet NCX1 splice variants display a
markedly increased sensitivity to pharmacological inhibi-
tors, resulting in the glucose-sensitive augmentation of
insulin secretion. These results identify a novel glucose-
dependent pathway that possesses desirable pharmacolog-
ical properties for future drug discovery.
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